Vertex Change In Cash from 2010 to 2024

VRTX Stock  USD 468.13  3.57  0.77%   
Vertex Pharmaceuticals Change In Cash yearly trend continues to be fairly stable with very little volatility. Change In Cash is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vertex Pharmaceuticals Change In Cash regression line of annual values had r-squared of  0.15 and arithmetic mean of  669,674,600. View All Fundamentals
 
Change In Cash  
First Reported
1991-09-30
Previous Quarter
-4.6 B
Current Value
668 M
Quarterly Volatility
517.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
       Timeline  

Vertex Change In Cash Regression Statistics

Arithmetic Mean669,674,600
Geometric Mean252,846,265
Coefficient Of Variation167.88
Mean Deviation760,439,013
Median232,123,000
Standard Deviation1,124,223,342
Sample Variance1263878.1T
Range3.9B
R-Value0.39
Mean Square Error1151793.6T
R-Squared0.15
Significance0.15
Slope98,578,764
Total Sum of Squares17694293.7T

Vertex Change In Cash History

2024-132.7 M
2023-139.7 M
20223.7 B
2021811.2 M
20202.9 B
2019462.4 M
2018990.7 M

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Change In Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash-139.7 M-132.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.